US Pharma MarketingThe post Beeline Medicines’ Phase II SLE trial of afimetoran meets primary endpoint appeared first on Clinical Trials Arena.
Beeline Medicines’ Phase II SLE trial of afimetoran meets primary endpoint
Beeline Medicines has announced that its global Phase II clinical trial involving adults with active moderate-to-severe systemic lupus erythematosus (SLE), evaluating afimetoran, achieved the primary endpoint. Participants in the trial received once-daily oral afimetoran or placebo alongside standard background therapies. The trial enrolled 248 adults aged 18 to 70 with moderate-to-severe SLE. Credit: Jarun Ontakrai / Shutterstock.com. Beeline Medicines has announced that its global Phase II clinical trial involving adults with active moderate-to-severe systemic lupus erythematosus (SLE), evaluating afimetoran, achieved the primary endpoint. The trial showed that all three doses of afimetoran resulted in higher SLE Responder Index-4 (SRI-4) response…
Beeline Medicines has announced that its global Phase II clinical trial involving adults with active moderate-to-severe systemic lupus erythematosus (SLE), evaluating afimetoran, achieved the primary endpoint.
Source: Clinical Trials Arena